Systemic immune responses in Alzheimer's disease: In vitro mononuclear cell activation and cytokine production

Journal of Alzheimer's Disease

Volumn 21, Issue 1, 2010, Pages 181-192

  Pellicanò, Mariavaleria ^a   Bulati, Matteo ^a   Buffa, Silvio ^a   Barbagallo, Mario ^a   Di Prima, Anna ^a   Misiano, Gabriella ^a   Picone, Pasquale ^b   Di Carlo, Marta ^b   Nuzzo, Domenico ^b   Candore, Giuseppina ^a   Vasto, Sonya ^a   Lio, Domenico ^a   Caruso, Calogero ^a   Colonna Romano, Giuseppina ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

Alzheimer's disease; chemokine; cytokine; PBMC; rA 42

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CD36 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CYTOKINE; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; SEX DIFFERENCE; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 77954977892     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091714     Document Type: Article

References (43)

1. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
2. Rafili MS, Aisen PS (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med 7, 7.
3. Vasto S, Candore G, Listi F, Balistreri CR, Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C (2008) Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 58, 96-105.
4. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
5. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation in Alzheimer's disease. Neuroinflammation Working Group. Neurobiol Aging 21, 383-421.
6. Teeling JL, Perry VH (2009) Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 158, 1062-1073.
7. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C (2007) Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8, 1735-1745.
8. Listi F, Caruso C, Lio D, Colonna-Romano G, Chiappelli M, Licastro F, Candore G (2010) Role of COX-2 and 5-LO polymorphisms in Alzheimer's disease in a population from Northern Italy: implication for pharmacogenomics. J Alzheimers Dis 19, 551-557.
9. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Camma C, Lio D, Caruso C (2009) Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 61, 60-68.
10. Di BonaD, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C (2008) Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev 59, 155-163.
11. Wyss-Coray T (2006) Inflammation in Alzheimer Disease: Driving force, bystander or beneficial response? Nat Med 12, 1005-1015.
12. Britschgi M, Wyss-Coray T (2007) Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 82, 205-233.
13. Rogers J, Luber-Narod J, Styren SD, Civin WH (1998) Expression of immune system associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9, 339-349.
14. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 7, 221-232.
15. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer's disease. J Clin Invest 112, 415-422.
16. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37, 943-948.
17. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D (2005) Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 40, 165-171.
18. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH (2007) Peripheral T cells overex-press MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 28, 485-496.
19. Reale M, Iarlori C, Feliciani C, Gambi D (2008) Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 14, 147-159.
20. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derho-vanessian E, Goldeck D, Fulop T (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 17, 91-103.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 34, 939-944.
22. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders: DSM-III-R, 3rd revised ed. Washington (DC), American Psychiatric Association.
23. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D (2004) Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroim-munol 148, 162-171.
24. Carrotta R, Di Carlo M, Manno M, Montana G, Picone P, Romancino D, San Biagio PL (2006) Toxicity ofrecombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin Paracentrotus lividus. FASEBJ 20, 1916-1917.
25. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production ofreactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160, 101-112.
26. Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 28, 1163-1169.
27. Xue S, Xu D, Yang X, Dong W (2009) Alterations in lymphocyte subset patterns and co-stimulatory molecules in patients with Alzheimer disease. Chin Med J122, 1469-1472.
28. Raichartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M, Cichkremer G, Schott K (2007) Altered lymphocyte distribution in Alzheimer's disease. J Psych Res 41, 174-178.
29. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD (2003) CD36 mediates the innate host response to β-amyloid. J Exp Med 197, 1657-1666.
30. Colonna-Romano G, Bulati M, Aquino A, Vitello S, Lio D, Candore G, Caruso C (2008) B cell immunosenescence in the elderly and in centenarians. Rejuvenation Res 11, 433-439.
31. Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Pellicano M, Rizzo C, Scapagni-ni G, Vasto S (2010) Inflammation, cytokines, immune response, ApoE and cholesterol, oxidative stress in Alzheimer disease: therapeutics implications. Rejuvenation Res 13, 301-313.
32. Gaskin F, Finley J, Fang Q, Xu S, Fu SM (1993) Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. JExpMed 177, 1181-1186.
33. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188, 117-127.
34. Stuart LM, Bell SA, Stewart CR, Silver JM, Richard J, Goss JL, Tseng AA, Zhang A, El Khoury JB, Moore KJ (2007) CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. J Biol Chem 282, 27392-27401.
35. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD (1995) An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogene-sis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 155, 5003-5010.
36. Wekerle H (1993) T-cell autoimmunity in the central nervous system. Intervirology 35, 95-100.
37. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV (2003) Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 116, 4615-4628.
38. Iarlori C, Gambi D, Gambi F, Lucci I, Feliciani C, Salvatore M, Reale M (2005) Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Exp Gerontol 40, 605-611.
39. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
40. Di Bona D, Scapagnini G, Candore G, Castiglia L, Colonna-Romano G, Duro G, Nuzzo D, Iemolo F, Lio D, Pellicano M, Scafidi V, Caruso C, Vasto S (2010) Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des 16, 684-691.
41. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoen-cephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
42. Fillit H, Hess G, Hill J, Bonnet P, Toso C (2009) IV im-munoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73, 180-185.
43. Scapagnini G, Caruso C, Vasto S, Pascale A, Romeo L, D'Agata V, Intrieri M, Sapere N, Li Volti G (2010) Genetic risk factors and candidate biomarkers for Alzheimer's disease. FrontBiosci (Schol Ed) 2, 616-622.